Allogene Therapeutics, Inc.
ALLO
$2.13
$0.073.40%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 32.00M | 28.63M | 31.16M | 40.16M | 50.20M |
| Gross Profit | -32.00M | -28.63M | -31.16M | -40.16M | -50.20M |
| SG&A Expenses | 14.09M | 13.77M | 13.74M | 14.28M | 14.99M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 46.09M | 42.40M | 44.90M | 54.44M | 65.19M |
| Operating Income | -46.09M | -42.40M | -44.90M | -54.44M | -65.19M |
| Income Before Tax | -42.61M | -38.81M | -41.40M | -50.94M | -59.73M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -42.61M | -38.81M | -41.40M | -50.94M | -59.73M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -42.61M | -38.81M | -41.40M | -50.94M | -59.73M |
| EBIT | -46.09M | -42.40M | -44.90M | -54.44M | -65.19M |
| EBITDA | -43.22M | -39.35M | -41.80M | -51.33M | -62.09M |
| EPS Basic | -0.18 | -0.17 | -0.19 | -0.23 | -0.28 |
| Normalized Basic EPS | -0.11 | -0.11 | -0.12 | -0.14 | -0.17 |
| EPS Diluted | -0.18 | -0.17 | -0.19 | -0.23 | -0.28 |
| Normalized Diluted EPS | -0.11 | -0.11 | -0.12 | -0.14 | -0.17 |
| Average Basic Shares Outstanding | 240.29M | 226.03M | 222.04M | 218.93M | 215.36M |
| Average Diluted Shares Outstanding | 240.29M | 226.03M | 222.04M | 218.93M | 215.36M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |